Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Foghorn Therapeutics (FHTX) Other Non Operating Income (2020 - 2025)

Foghorn Therapeutics (FHTX) has 5 years of Other Non Operating Income data on record, last reported at $1.4 million in Q4 2024.

  • For Q4 2024, Other Non Operating Income rose 107.37% year-over-year to $1.4 million; the TTM value through Dec 2024 reached $4.2 million, up 47.05%, while the annual FY2024 figure was $4.2 million, 47.05% up from the prior year.
  • Other Non Operating Income reached $1.4 million in Q4 2024 per FHTX's latest filing, up from $1.2 million in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $2.5 million in Q3 2022 and bottomed at -$1.2 million in Q4 2021.
  • Average Other Non Operating Income over 5 years is $719700.0, with a median of $679000.0 recorded in 2021.
  • The widest YoY moves for Other Non Operating Income: up 4507.14% in 2021, down 312.77% in 2021.
  • A 5-year view of Other Non Operating Income shows it stood at $564000.0 in 2020, then crashed by 312.77% to -$1.2 million in 2021, then skyrocketed by 152.0% to $624000.0 in 2022, then increased by 8.65% to $678000.0 in 2023, then surged by 107.37% to $1.4 million in 2024.
  • Per Business Quant database, its latest 3 readings for Other Non Operating Income were $1.4 million in Q4 2024, $1.2 million in Q3 2024, and $783000.0 in Q2 2024.